Document Detail


Successful treatment of early thrombosis of HeartWare left ventricular assist device with intraventricular thrombolytics.
MedLine Citation:
PMID:  22734996     Owner:  NLM     Status:  MEDLINE    
Abstract/OtherAbstract:
In the last few years, left ventricular assist devices (LVADs) have moved to the forefront in the management of patients with advanced heart failure. Pumps have gradually become smaller and more efficient and have clearly demonstrated survival benefits and improvement in functional status and quality of life in patients with advanced heart failure. Despite impressive advances in device technology, risk of severe complications remains, such as device thrombosis. A 62-year-old man who underwent HeartWare LVAD implantation as a bridge to cardiac transplant was admitted 18 days after device implantation with severe shortness of breath, fatigue and lethargy; he was found to have increased pump flows with high power demands and evidence of cardiogenic shock. An echocardiogram showed an echo density at the inflow cannula that was suggestive of thrombosis. Laboratory data showed evidence of hemolysis. He was treated successfully with intraventricular tissue plasminogen activator with rapid resolution of his symptoms and return of LVAD flow and power consumption to baseline. The patient was discharged with no complications or recurrence of thrombosis and received a successful transplant 1 month later.
Authors:
Abdallah Kamouh; Ranjit John; Peter Eckman
Related Documents :
22649726 - Left ventricular diastolic dysfunction in dialysis patients assessed by novel speckle t...
22118006 - Relationship between cytochrome p450 2c19*2 polymorphism and stent thrombosis following...
16368296 - Overview of acute decompensated heart failure in argentina: lessons learned from 5 regi...
10980216 - Underutilization and clinical benefits of angiotensin-converting enzyme inhibitors in p...
21804776 - Cardiac workup of ischemic stroke.
12574896 - The effect of aortic valve replacement on coronary flow reserve in patients with a norm...
Publication Detail:
Type:  Case Reports; Journal Article    
Journal Detail:
Title:  The Annals of thoracic surgery     Volume:  94     ISSN:  1552-6259     ISO Abbreviation:  Ann. Thorac. Surg.     Publication Date:  2012 Jul 
Date Detail:
Created Date:  2012-06-27     Completed Date:  2012-09-04     Revised Date:  2013-05-01    
Medline Journal Info:
Nlm Unique ID:  15030100R     Medline TA:  Ann Thorac Surg     Country:  Netherlands    
Other Details:
Languages:  eng     Pagination:  281-3     Citation Subset:  AIM; IM    
Copyright Information:
Copyright © 2012 The Society of Thoracic Surgeons. Published by Elsevier Inc. All rights reserved.
Affiliation:
Division of Cardiovascular Medicine, University of Minnesota Medical Center, Minneapolis, Minnesota 55455, USA. kamou001@umn.edu
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms
Descriptor/Qualifier:
Fibrinolytic Agents / therapeutic use*
Heart Ventricles*
Heart-Assist Devices / adverse effects*
Humans
Male
Middle Aged
Thrombosis / drug therapy*
Tissue Plasminogen Activator / therapeutic use*
Chemical
Reg. No./Substance:
0/Fibrinolytic Agents; EC 3.4.21.68/Tissue Plasminogen Activator
Comments/Corrections
Comment In:
Ann Thorac Surg. 2013 Apr;95(4):1508   [PMID:  23522225 ]
Ann Thorac Surg. 2013 Apr;95(4):1508-9   [PMID:  23522224 ]

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine


Previous Document:  Pseudocoarctation of the aorta secondary to aortic intimal sarcoma.
Next Document:  Recurrent atrioventricular groove intramuscular arteriovenous malformation.